Balanced news tone
News Sentiment
ACE sentiment intelligence
Ascelia Pharma AB (publ) news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-17.8% over one week, -76.4% over four weeks, trend inactive, and below fair value.
Ascelia Pharma Restructures and Cuts Costs to Sharpen Focus on Orviglance
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Ascelia Pharma Restructures and Cuts Costs to Sharpen Focus on Orviglance
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Jul 2026 12:05
- Source
- TipRanks
Ascelia Pharma Defends Orviglance Trial After FDA Rejection, Shares Plunge 79% in 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 17:35
- Source
- finance.biggo.com
Ascelia Pharma Defends Orviglance Data After FDA Complete Response Letter
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 17:05
- Source
- TipRanks
Ascelia Pharma AB (publ)'s (STO:ACE) Path To Profitability
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 07:00
- Source
- simplywall.st